Preliminary Study for Selective Detection of the CD8+ Myelin Specific
Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS).
What it found
We found no results in the registry or in papers.
This trial finished 10 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Blood samples
What it measured
Main measures
Analysis of pentamers (> 0,1 % of the CD3 + CD8 + T-cells) will be statistically compared between the 3 groups of patients.
6 months after the inclusion
Immune response
Other measures (3)
The results will be correlated with the patients clinical
6 months after the inclusion
Disability progressionRelapsesThe results will be correlated with the patients MRI data
6 months after the inclusion
MRI lesionsDescription of lymphocyte immunophenotyping and dosage of immunoglobulins in patients treated with Natalizumab
6 months after the inclusion
Immune response
Who could take part
Relapsing MS · 18 and over
Show the full criteria
Inclusion criteria
Group 1: HLA-A2 patients whose Multiple Sclerosis has just been diagnosed * 18 year old and older patients, * HLA-A2 Patients with Multiple Sclerosis or clinically isolated syndrome at high risk of being affected by Multiple Sclerosis (criteria of spatial scattering according to the 2010 or 2005 McDonald's criteria) * Patients without treatment or treated with immunomodulating therapy * Patients affiliated to health insurance coverage * Information and comprehensive agreement signed by the patient and the investigator Group 2: HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder * 18 year old and older patients, * HLA-A2 patients hospitalized in the neurology department * Patient not affected by Multiple Sclerosis or a related inflammatory disorder * Affiliated or profitable subject of a national insurance scheme * Patients affiliated to health insurance coverage * Information and comprehensive agreement signed by the patient and the investigator Group 3: HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy * 18 year old and older patients, * HLA-A2 patients with relapsing remitting (RR) MS fulfilling McDonald 2005 or 2010 Multiple Sclerosis diagnostic criteria * Patients treated by Natalizumab therapy for at least 3 months * Patients affiliated to health insurance coverage * Information and comprehensive agreement signed by the patient and the investigator
Exclusion criteria
Group 1 and 3: * Patients undergoing immunosuppressive therapy at present or in the past except Natalizumab * Pregnant women Group 2: * Patients undergoing immunosuppressive therapy at present or in the past * Patients affected by Multiple Sclerosis or a related disorder * Pregnant women
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Most experts in the field consider Multiple Sclerosis as the main auto immune disease of the central nervous system. In spite of many works, the data in the literature concerning the antigens targeted by the CD8+ T-Cell response are still contradictory and insufficient.
Loading reviews and guidelines…
History
Started
Nov 2014
Main results due
Feb 2016
Finished
Feb 2016